Initial evaluation of the patient with lung cancer: Symptoms, signs, laboratory tests, and paraneoplastic syndromes - ACCP evidenced-based clinical practice guidelines (2nd edition)

被引:126
作者
Spiro, Stephen G.
Gould, Michael K.
Colice, Gene L.
机构
[1] UCL Hosp, Dept Resp Med, London WC1E 6AU, England
[2] Vet Affairs Palo Alto Care Syst, Stanford, CA USA
[3] Washington Hosp Ctr, Pulm Crit Care & Resp Serv, Washington, DC 20010 USA
关键词
evaluation; laboratory tests; paraneoplastic syndrome; signs; symptoms;
D O I
10.1378/chest.07-1358
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: This chapter of the guidelines is intended to provide an evidence-based assessment of the initial evaluation of patients recognized as having lung cancer and the recognition of paraneoplastic syndromes. Methods: The current medical literature that is applicable to this issue was identified by a computerized search and was evaluated using standardized methods. Recommendations were framed using the approach described by the Health and Science Policy Committee of the American College of Chest Physicians. Results: Patients with lung cancer usually present with multiple symptoms, both respiratory related and constitutional. There is usually a time delay between symptom recognition by the patient and the ultimate diagnosis of lung cancer by the physician. Whether this time delay impacts prognosis is unclear, but delivering timely and efficient care is an important component in its own right. Lung cancer may be accompanied by a variety of paraneoplastic syndromes. These syndromes may not necessarily preclude treatment with a curative intent. Conclusions: The initial evaluation of the patient with known or suspected lung cancer should include an assessment of symptoms, signs, and laboratory test results in a standardized manner as a screen for identifying those patients with paraneoplastic syndromes and a higher likelihood of metastatic disease.
引用
收藏
页码:149S / 160S
页数:12
相关论文
共 90 条
[81]  
SPIRO SG, 1995, RESP MED
[82]   Digital clubbing and lung cancer [J].
Sridhar, KS ;
Lobo, CF ;
Altman, RD .
CHEST, 1998, 114 (06) :1535-1537
[83]   HYPERTROPHIC PULMONARY OSTEOARTHROPATHY [J].
STENSETH, JH ;
CLAGETT, OT ;
WOOLNER, LB .
DISEASES OF THE CHEST, 1967, 52 (01) :62-&
[84]  
Swash M., 1990, CURRENT THERAPY NEUR, P236
[85]   1976 CALDWELL LECTURE - VARYING MANIFESTATIONS OF PERIPHERAL PULMONARY NEOPLASMS - RADIOLOGIC-PATHOLOGIC CORRELATIVE STUDY [J].
THEROS, EG .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1977, 128 (06) :893-914
[86]   PROGNOSTIC VALUE OF THE SUPERIOR VENA-CAVA SYNDROME AS THE PRESENTING SIGN OF SMALL CELL ANAPLASTIC CARCINOMA OF THE LUNG [J].
VANHOUTTE, P ;
DEJAGER, R ;
LUSTMANMARECHAL, J ;
KENIS, Y .
EUROPEAN JOURNAL OF CANCER, 1980, 16 (11) :1447-1450
[87]  
VINCENT RG, 1977, CANCER, V39, P1647, DOI 10.1002/1097-0142(197704)39:4<1647::AID-CNCR2820390439>3.0.CO
[88]  
2-H
[89]   PARA-ENDOCRINE TUMOR ACTIVITY WITH EMPHASIS ON ECTOPIC ADH SECRETION - GENETIC, DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC ASPECTS [J].
VORHERR, H .
ONCOLOGY, 1974, 29 (05) :382-416
[90]   SUPERIOR VENA-CAVA SYNDROME - THE MYTH THE FACTS [J].
YELLIN, A ;
ROSEN, A ;
REICHERT, N ;
LIEBERMAN, Y .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 141 (05) :1114-1118